BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10078785)

  • 21. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
    Cho BC; Kim JH; Kim CB; Sohn JH; Choi HJ; Lee YC; Ahn JB
    Oncol Rep; 2006 Mar; 15(3):621-7. PubMed ID: 16465422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study.
    Cascinu S; Fedeli A; Catalano G
    Cancer Chemother Pharmacol; 1994; 34(1):72-4. PubMed ID: 8174205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The UFT/leucovorin/etoposide regimen for the treatment of advanced gastric cancer. Oncopaz Cooperative Group.
    González Barón M; Espinosa E; Feliu J; Ordóñez A; Zamora P; de Castro J; García Girón C; García Alfonso P; Garrido P; Belón J; Lomas M
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):109-12. PubMed ID: 9348581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC).
    Cavanna L; Artioli F; Codignola C; Lazzaro A; Rizzi A; Gamboni A; Rota L; Rodinò C; Boni F; Iop A; Zaniboni A
    Am J Clin Oncol; 2006 Aug; 29(4):371-5. PubMed ID: 16891864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer.
    Yeh KH; Lu YS; Hsu CH; Lin JF; Hsu C; Kuo SH; Li SJ; Cheng AL
    Oncology; 2005; 69(1):88-95. PubMed ID: 16088236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant chemotherapy with cisplatin, etoposide, fluorouracil and leucovorin for gastric carcinoma.
    Papadakou M; Xydakis E; Bonios M; Makropoulou E; Boukis C; Kakavoulis T; Karaliotas C; Panagos G
    J BUON; 2006; 11(3):285-9. PubMed ID: 17309151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of advanced gastric cancer with etoposide, folinic acid, and fluorouracil in the clinical setting: efficacy of therapy and value of serum tumor markers.
    Schulze-Bergkamen H; Zuna I; Teufel A; Stremmel W; Rudi J
    Med Oncol; 2002; 19(1):43-53. PubMed ID: 12025890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer.
    Petrioli R; Sabatino M; Roviello F; Marrelli D; Nastri G; Marsili S; Correale P; Pozzessere D; Messinese S; De Martino A; Tani F; Marzocca G; Lorenzi M; Civitelli S; Tanzini G; Pinto E; Francini G
    Hepatogastroenterology; 2005; 52(65):1626-30. PubMed ID: 16201130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer--a phase II study in elderly patients or patients with cardiac risk.
    Wilke H; Preusser P; Fink U; Achterrath W; Lenaz L; Stahl M; Schober C; Link H; Meyer HJ; Lucke B
    Invest New Drugs; 1990 Feb; 8(1):65-70. PubMed ID: 2345071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-Fluorouracil, methotrexate, leucovorin, CDDP and epirubicin (FEPMTX): a wide-spectrum regimen of salvage chemotherapy for high-grade advanced gastric cancer.
    Kinoshita K; Yonemura Y; Sawa T; Miyata T; Sakuma H; Matsuki N; Tanaka S; Fushida S; Fujimura T; Mok YJ; Kim BS; Lee JI; Choi DW; Song YJ; Yang DH; Kwon SJ; Tanaka M; Miyazaki I
    Hepatogastroenterology; 2003; 50(53):1716-9. PubMed ID: 14571825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Advanced gastric cancer curatively resected following combined neoadjuvant chemotherapy--report of a case].
    Koike N; Ohwada S; Ogawa T; Kawashima K; Takeyoshi I; Sato Y; Kamiyama H; Morishita Y
    Gan To Kagaku Ryoho; 1998 May; 25(6):919-23. PubMed ID: 9617332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer.
    Bokemeyer C; Hartmann JT; Lampe CS; Clemens MR; Quietzsch D; Forkmann L; Kanz L
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-96-S19-100. PubMed ID: 9427277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination chemotherapy comprising 5-fluorouracil, leucovorin, etoposide, and cis-diamminedichloroplatinum for the treatment of advanced gastric cancer.
    Mochizuki F; Fujii M; Kasakura Y; Yamagata M; Kochi M; Wakabayashi K; Kanamori N; Takayama T
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):493-6. PubMed ID: 12242513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
    Matsubara J; Shimada Y; Takashima A; Takahari D; Hirashima Y; Okita NT; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shirao K
    Jpn J Clin Oncol; 2008 Aug; 38(8):540-6. PubMed ID: 18628316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer.
    Kos FT; Uncu D; Ozdemir N; Budakoglu B; Odabaş H; Abali H; Oksuzoglu B; Aksoy S; Zengin N
    Chemotherapy; 2011; 57(3):230-5. PubMed ID: 21597287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
    Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
    J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.
    Idelevich E; Karminsky N; Dinerman M; Katsenelson RL; Zvi NB; Baruch NB; Biran H; Man S; Shani A
    Acta Oncol; 2007; 46(3):324-9. PubMed ID: 17450467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group.
    Içli F; Celik I; Aykan F; Uner A; Demirkazik A; Ozet A; Ozgüroğlu M; Taş F; Akbulut H; Firat D
    Cancer; 1998 Dec; 83(12):2475-80. PubMed ID: 9874451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.